BR2022-1

· Boryung Pharmaceutical Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BR2022-1, covering 2025-07-16 to 2025-07-16. Get the full timeline:

Most recent: Clinical Trial Update: A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer [Phase 1]

See pricing